ArticleOncotarget2019

Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy.

Caitlin D Lowery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.